|1.||Rizzieri, David A: 2 articles (05/2011 - 02/2002)|
|2.||Wang, Chenyang: 1 article (11/2014)|
|3.||Li, Jieshou: 1 article (11/2014)|
|4.||Li, Qiurong: 1 article (11/2014)|
|5.||He, Qin: 1 article (11/2014)|
|6.||Tang, Chun: 1 article (11/2014)|
|7.||Coles, Alasdair J: 1 article (01/2013)|
|8.||Brown, J William L: 1 article (01/2013)|
|9.||Steinherz, Peter: 1 article (08/2012)|
|10.||Kobos, Rachel: 1 article (08/2012)|
05/01/1996 - "Patients with severe rheumatoid arthritis who had failed treatment with conventional therapies were treated with a course of five or 10 daily intravenous infusions of CAMPATH-1H, a humanized antibody against the CD52 antigen, resulting in profound depletion of peripheral blood mononuclear cells. "
04/05/1997 - "CAMPATH-1H is a recombinant humanized murine monoclonal immunoglobulin (IgG1) which recognizes the CDw52 antigen of human lymphocytes, and has been the subject of clinical trials for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. "
|2.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
08/01/2012 - "Alemtuzumab is a humanized chimeric mAbthat targets the CD52 antigen, it is currently approved for relapsed/refractory and high-risk untreated chronic lymphocytic leukemia (CLL). "
02/01/2002 - "CAMPATH-1H, a humanized monoclonal antibody against the CD52 antigen, has been used with some success in other lymphoproliferative diseases, especially chronic lymphocytic leukemia. "
05/01/2009 - "Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy."
12/01/2007 - "Alemtuzumab (Campath-1H), a monoclonal antibody that targets the CD52 antigen, has been approved for the treatment of fludarabine-refractory chronic lymphocytic leukemia. "
04/01/2007 - "Alemtuzumab is a humanized (IgG(1)) rat monoclonal antibody to CD52 antigen and is currently used in the treatment of chronic lymphocytic leukemia (CLL) and other CD52-positive lymphoproliferative disorders. "
09/01/2007 - "Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells. "
09/01/2007 - "Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases."
08/01/2012 - "Two patients with chemotherapy-refractory, metastatic HS with tumors that expressed the CD52 antigen received a prolonged course of treatment with the anti-CD52 monoclonal antibody alemtuzumab. "
02/01/2002 - "This report demonstrates that tumor samples from patients with mantle cell lymphoma express the CD52 antigen and suggests that CAMPATH-1H should be studied in patients with mantle cell lymphoma."
11/01/1998 - "Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells."
04/01/1994 - "Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas."
01/01/2002 - "CAMPATH-1H (CP-1H) is a humanized monoclonal antibody directed against the CD52 antigen with promising therapeutic effects in patients with small cell lymphocytic non-Hodgkin's lymphomas (NHL) of B- and T-cell type. "
|2.||Immunoglobulin G (IgG)
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation